Johns Hopkins University will begin two clinical trials of convalescent blood plasma to treat COVID-19 next week.
Convalescent blood plasma is plasma derived from the blood of COVID-19 survivors.
According to UPI, researchers said the trials will focus on healthcare workers and nursing home residents.
Researchers theorize that the blood from recovered patients contains antibodies that may fight the virus.
Doctors hope that treatment will cut down on the need to hospitalize patients.
The goal is to give the plasma to patients while they are at home, before respiratory distress sets in.
